“This new financing marks an important milestone in our growth and will contribute to the significant progress we are making with regulators and with our commercial partners, who are already running studies with digital twins and demonstrating their value in generating robust evidence and increasing the potential for trial success,” Charles K. Fisher, PhD, founder and CEO of Unlearn.AI, said in a statement. “Clinical trials are facing a number of persistent challenges that have only been exacerbated in recent weeks. With support from our forward-thinking investors and industry partners, we are excited to continue growing our exceptional team and advancing the science behind our first-of-its-kind digital twin approach.”

As a result of this funding round, Francisco Gimenez, PhD, 8VC principal, will now serve on the Unlearn Board of Directors.

“Unlearn's pioneering use of Digital Twins will limit the number of patients that need to go on placebo while also reducing overall trial enrollment time,” Gimenez said in the same statement. “As investors at the intersection of healthcare and technology, we're passionate about companies that pair cutting-edge computational techniques and innovative business models to meaningfully improve patient care.”